drugset / Trial / NCT05891483

Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps

NCT05891483 ↗

Phase 2 Unknown 114 enrolled Guangdong Hengrui Pharmaceutical Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is being conducted to evaluate the efficacy, and safety of SHR-1905 injection in subjects with chronic rhinosinusitis with nasal polyps (CRSwNP), as well as to explore the reasonable dosage of SHR-1905 injection for CRSwNP.

Timeline

Start
2023-09-04
Primary completion
2026-02
Completion
2026-02

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-1905 Monoclonal antibody — —